The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- Registration Number
- NCT02395640
- Lead Sponsor
- Fudan University
- Brief Summary
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
- Detailed Description
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 438
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EOX Capecitabine Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； XELOX Oxaliplatin oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； EOX Epirubicin Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； XELOX Capecitabine oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； EOX Oxaliplatin Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
- Primary Outcome Measures
Name Time Method progression free survival 7 months
- Secondary Outcome Measures
Name Time Method overall survival 10 months quality of life questionnaire 2 months Number of Participants with Adverse Events 2 months overall response rate 2 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie XELOX and EOX regimens in advanced gastric cancer treatment?
How does XELOX compare to EOX as first-line therapy for HER2-negative gastric cancer in phase 3 trials?
Which biomarkers correlate with response to capecitabine-oxaliplatin or epirubicin-oxaliplatin regimens in gastric adenocarcinoma?
What are the distinct adverse event profiles of XELOX versus EOX in metastatic gastric cancer patients?
How do XELOX and EOX regimens compare to other fluoropyrimidine-based combinations like FLOT in treating gastroesophageal junction cancer?
Trial Locations
- Locations (1)
Fudan University Cancer Hospital
🇨🇳ShangHai, Shanghai, China
Fudan University Cancer Hospital🇨🇳ShangHai, Shanghai, China